relationships between patients and using amgen's medicines. intelligence in even trying to figure that out? >> yeah. what's happening right now in most of these life sciences companies is you have a master data management. typically it's patient data, clinical data, provider data as well as the actual drugs they're working on every life science company is doing it as is amgen, johnson & johnson. we just announced an acquisition, i wanted to announce it on your show a little company call all sight. the leader in ai powered customer insights. so how to get customer inviting sights, applying machine learning and ai. and that's the platform that is driving these next generation use of data in companies like life sciences companies. >> i saw you as a dream force. i know you a close relationship with salesforce. this something that would be ingrated in your relationship with salesforce? >> it is all these companies like salesforce, adobe, et cetera, they are the ones providing the last mile with the customers, whether it's through social media, e-ma

amgen made aacimilar move in october. sanofi down a fraction 42.43. ample mgem was off a kick at 185.79. >>> a rise in profit in the fourth quarter. the online et indication company says subscriber count grew by more than 30%. as a result, it's increasing revenue guidance for this year. that sent the stock higher in initial after-hours trading this evening. finished the regular session up 1% to>>34.80. used to be older americans would sell homes and downsize e kids moved out. today an increasing number are aoosing in place having an impact on home buyers of all ages. >> reporter: 64-year-old lewis is busy building a elevatoro i his small maryland home. >> i took the middle line between the up and lower level and opened the shaft which i put a lift in ho these can be aging in place house. >> reporter: he plans to grow d in h current neighborhood as look as he can and he is not alone. >> people love their s.ho it's their chief investment. they love the control they get in their own house the. >> reporter: estimat on1.6 million homes in a housing mket in

companies don't have revenues but the science is behind it not all are created equal, but a company like amgen very reasonable valuation, tremendous sheet. a company that can't get over $195, $200, but i still think there is room there as well. >> and our next guest says the charts are pointing to trouble for the group. carter worth is breaking it down >> too fast as some of the areas you are talking about. this is maybe the most so take some action before as they say someone does it for you. percentage change from the low on december 4t tth xbi, up the s at 37. ibb, cap weighted toward celgene, so forth, up 26 there is the market up 20. and of course hemalth care up te least. so let's zero in on biotech in particular and the real problem is, and tim you referred to this, this has been poor relative performance for quite some time. here is the chart. i see something that is just stuck at prior highs now, if we put in relative performance, this is the real issue. if i were to draw a line, there was alpha coming off the low yes? because what has happened since this is that basically after the in

i amgen fer casarian and i work here at san francisco international airport. the idea for therapy dogs got started the day after 9/11. an employee brought his therapy dog to work after 9/11 and he was able to see how his dog was able to relieve passenger's jitter. when we first launched the program back in 2013, our main goal was to destress our passengers however what we quickly found is that our animals were helping us find a way to connect with our pang. passengers. we find there are a lot of people traveling through the airport who are missing their pets and who are on their road a lot and can't have pets and we have come in contact with a lot of people recently who have lost pet. >> i love the wag brigade. >> one of my favorite parts is walking into the terminals and seeing everybody look up from their device, today everybody is interacting on their cell phone or laptop and we can walk into the terminal with a dog or a pig and people start to interact with each other again and it's on a different level. more of an emotional level. >> i just got off an 11.

when the term executive is used i amgen rally working. i had no choice but to work very long hours. acting chief of staff mick mulvaney had to say about executive time. >> there's a report the president spend a majority of his time in executive time. he's off tweeting away and gossiping and not working? >> i read that. i get those schedules. that's probably the closest thing to a public schedule we put out. it's not very sensitive. 400 people get that schedule. it's not that valuable of information. that executive time is to allow the president to prep for the next meeting, to debrief from the previous meeting. phone calls start at 6:30 in the morning until 11:00 at night. i can assure you the gentleman is working more than what's on that calendar. >> amy klobuchar officially announced she's running for president. the minnesota senator held an outdoor rally in minnesota yesterday in blizzard-like conditions. >> i don't have a political machine. i don't come from money. but what i do have is this. i have grit. i have family. i have friends. i have neighbors. and i have all of you who

we will speak with some of the biggest names, including amgen china and-cham business management.ng you some of the stock movers this morning, including socgen as they are said to weigh thousands of job .uts at its investment bank you can see shares trading up more than 2% in paris for this is bloomberg. ♪ matt: welcome back to bloomberg: markets, this is the european open. looking at gains across the board, not huge size, at least we have got huge direction, up on the major equity indices. let's bring you three of this morning's biggest corporate stories. we are in berlin looking at kraft heinz, looking at paris at the socgen report, and in frankfurt, we are covering what has been a massive saga in germany. hass start with you on what been the most read a story of the day, four hours and hours. kraft heinz is sinking, why? >> kraft heinz have an absolutely awful day, the stock sinking with a 20%. they have written down the value of some of their beloved assets, but there is also an sec investigation into some of their procurement practices. third of all, the/the dividend, and all

allowing the atloyees to teach part-time one of these colleges and universities. , anow for example amgen manufacturer and pharmaceutical manufacturer, that's a facility in my district. i know that they had some of their employees teach at colleges and universities in a great collaboration between the two. wet's just one example, but need obviously more people in the education field teaching the next generation. health care, for example, is a great example of where there's a real gap and a need for more nurse educators. there's a waiting list of students wanting to get into nursing programs. i have a young niece in a nursing program right now and i know that the waiting list of students who want to go in and the reason they don't have a way , they don't have enough educators because as the caller pointed out, it just doesn't pay enough. a first-year news -- nursing student for example will be earning more than the nurse educator teaching the next generation. i know in other states across , if the nurse wants to become a nurse educator, there are some programs to help pay down the student

>>amgen has a license in the united states right now to produce. >> but you locked them for five right? >> no, we did not lock them. we license to them. >> did you see them? >> we did. yes. >> and you entered an agreement with them that accommodated both your needs and their needs, i assume? >> we licensed them eyepatch and portfolio. they pay us a royalty on the patent portfolio. that is essentially it. >> mr. chairman, i don't want to interrupt. senator cornyn is dead right. that is exactly the same point was going to make. >> mr. chairman could i make a --gestion, this topic is within the jurisdiction of the committee. by those of us like you and i've who are also on the judiciary committee that has jurisdiction over the patent system, i think this is an area we need to look into through our judiciary committee authorities as well. >> why don't you take that up with graham and i will make sure i'm back you up on it? >> i look forward to your backup. >> and let me know what your conversation produces. >> thank you. menendez, would be carpenter. senator menendez. sen. menendez: let me